Cargando…

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering

Detalles Bibliográficos
Autores principales:	Jacob, Jubbin Jagan, Madhu, S V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959194/ https://www.ncbi.nlm.nih.gov/pubmed/35355912 http://dx.doi.org/10.4103/2230-8210.337826

Ejemplares similares

Expounding newer vistas in VEGF
por: Natarajan, Sundaram
Publicado: (2013)

Newer antidiabetic drugs and calorie restriction mimicry
por: Kalra, Sanjay, et al.
Publicado: (2016)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

TSH Receptor Antibodies (TRAb) Assay: An Underutilized Test in India
por: Jacob, Jubbin Jagan
Publicado: (2022)

Insulin Storage Guidance for Patients with Diabetes Using Insulin
por: Jacob, Jubbin Jagan
Publicado: (2023)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Melatonin - marvel in the making?
por: Umesh, Goneppanavar
Publicado: (2016)

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults
por: Zhu, Changzhen, et al.
Publicado: (2022)

Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
por: Hamasaki, Hidetaka
Publicado: (2018)

Falls, Fractures, and Mortality: The Role of Calcium and Vitamin D Replacement in Rural India
por: Paul, Thomas V., et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucocorticoid Use Audits
por: Jacob, Jubbin Jagan, et al.
Publicado: (2022)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

New concept of the glucagon‐like peptide‐1 signaling pathway on pancreatic insulin secretion
por: Kaku, Kohei
Publicado: (2019)

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
por: Bloomgarden, Zachary
Publicado: (2023)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications
por: Manandhar, Bikash, et al.
Publicado: (2014)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome, Getnet, et al.
Publicado: (2020)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
por: Marbury, Thomas C., et al.
Publicado: (2017)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid
por: Fernandes, Maria F., et al.
Publicado: (2022)

Direct cardiovascular effects of glucagon like peptide-1
por: Sheikh, Asfandyar
Publicado: (2013)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Equine glucagon-like peptide-1 receptor physiology
por: Kheder, Murad H., et al.
Publicado: (2018)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vkgll17iuq7vjdg7aq9knpheak